1. APRE Agenzia per la promozione della Ricerca Europea
Caterina Buonocore,
Health National Contact Point for Italy,
“Part of this presentation is taken from the official material produced by EC, DG Research, Unit F”.

2. AGENDA PRESENTAZIONE APRE SETTIMO PROGRAMMA QUADRO (7PQ)
Structure and scope of Health theme
Basic principles
Health 2013 Work programme key features / priorities
How to find partners
Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH, ENV…
Other funding opportunities for health researchers
Information sources

3. L' APRE è un Ente di ricerca non profit con obiettivo, sancito dall’articolo 3 del suo statuto, di promuovere la partecipazione italiana ai programmi di ricerca e sviluppo finanziati dalla Commissione Europea.
Prima realtà del suo genere in Italia, APRE nasce nel 1989 come “Task Force” del Ministero dell’Università e della Ricerca.
Nel 1990 viene poi costituita formalmente da Confindustria, ENEA, FAST e Mondimpresa
È sostenuta da numerose Università e organizzazioni private e pubbliche del mondo accademico, dell’industria e della finanza.
[COS’É APRE?]

4. Migliorare la “Qualità” della partecipazione italiana nei programmi europei di ricerca su sviluppo e innovazione.
Per conto del Ministero dell'Università e della Ricerca (MIUR), APRE ha lo scopo di fornire informazioni, supporto e assistenza sulle modalità di partecipazione ai programmi europei di ricerca e sviluppo tecnologico, ad enti pubblici, enti privati e persone fisiche.
Ospita la rete dei National Contact Point (NCP).
Assistenza
Formazione
Informazione
[MISSION]

5. [INTERLOCUTORI] Soci APRE Un po’ di numeri: 110 Soci di cui:
6 associazioni di categoria
34 enti di ricerca tra pubblici e privati
4 realtà appartenenti al mondo della finanza
5 organismi del sistema camerale
4 parchi scientifici
6 enti della pubblica amministrazione
51 università
APRE
Associazioni
industiali
Camere di Commercio
Parchi Scientifici
Università
Centri di ricerca
Industrie
Enti pubblici
Finanza
Soci APRE
[INTERLOCUTORI]

6. [RISORSE APRE – SPORTELLI LOCALI]
Per rafforzare il sistema della cooperazione tra istituzioni pubbliche e private attive nel settore della ricerca scientifica e tecnologica e promuovere e diffondere la ricerca europea a livello nazionale, APRE dispone di una rete di Sportelli regionali.
Gli Sportelli, oltre a fornire tutti i servizi specifici dell'APRE, costituiscono anche una sede per favorire le iniziative promosse dai Soci APRE presenti nella regione, supportando inoltre quelle portate avanti da parte di altre istituzioni ed organizzazioni impegnate nel campo della ricerca e dell'innovazione tecnologica
Ospitati e gestiti dai Soci APRE, gli Sportelli APRE sono punti di accesso alle informazioni ad operatività regionale e coordinati dalla sede centrale a Roma.
[RISORSE APRE – SPORTELLI LOCALI]

7. partecipazione ad eventi e giornate informative
APRE BRUSSEL offre ai soci:
partecipazione ad eventi e giornate informative
diffusione di informazioni aggiornate sulle politiche, iniziative ed opportunità sulla ricerca in Europa
collegamento diretto con vari attori della ricerca Europea (Istituzioni Europee, liaison office e organismi di ricerca degli Stati Membri, Confederazioni e Consorzi paneuropei)
accompagnamento agli incontri con i funzionari della Commissione Europea
la sala riunione per meeting internazionali dei progetti Europei di ricerca
[RISORSE APRE – SPORTELLO EUROPA]

8. Rappresentanza Italiana
Commissione Europea
Rappresentanza Italiana
Delegati Nazionali PQ
MIUR
APRE
(NCP) 1
In qualità di ente ospitante dei NCP, punti di contatto nazionale per il PQ, lavoriamo a servizio della CE che ci forma, coordinati dal MIUR, con i delegati del PQ tra le altre cose, per le attività di raccolta dei contributi scientifici dalla comnunità scientifica trasmessi poi alla Rappresentanza Ita.
[MISSION]

9. IN ITALIA: COMITATO DI PROGRAMMA SALUTE PUNTI DI CONTATTO NAZIONALI
Caterina Buonocore
APRE
Silvio Garattini (Mario Negri)
Stefano Vella
(ISS)
Caterina Buonocore
(APRE)
Bruno Mourenza
APRE
Alfredo Cesario
(IRCSS)

10. [MISSION] Proposta vincente
APRE ospita i Punti di contatto nazionale del VII Programma Quadro in Italia. Questi sono nominati dal Ministero dell'Università e della Ricerca (MUR) e riconosciuti dalla Commissione Europea.
Informazione
Conferenze
News Alert
Sito web (
Pubblicazioni
Assistenza
Informazione
Formazione
Essere un buon coordinatore
Preparazione della proposta
Come disseminare i risultati della ricerca
Proprietà intellettuale e Consortium Agreement
Formazione
Supporto prima dell’inizio del progetto (telefono, mail e incontri)
Identificazione del tema e del topic FP7
Verificare l’elegibilità della proposta
Pre-screening della proposta
Aiuto nell‘utilizzo dell’EPSS System
Proposta vincente
Supporto dopo l’inizio del progetto (telefono, mail e incontri)
Negoziazione
Management del progetto
Disseminazione dei risultati
Reporting
[MISSION]

11. COME SCEGLIERE IL BANDO GIUSTO IN UN PANORAMA ARTICOLATO
SALUTE NEL 7 PQ
COME SCEGLIERE IL BANDO GIUSTO IN UN PANORAMA ARTICOLATO

13. The 7th Framework programme (FP7)
Structure and scope of Health theme
Basic principles
Health 2013 Work programme key features / priorities
Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH…
Other funding opportunities for health researchers
Information sources

14. EU research policy Why ? How ? to improve quality of life and
to improve competiveness of Europe through collaboration
How ?
by pooling resources (funds for Framework Programme)
by coordinating national research programmes

15. Associazioni di pazienti
Università
Centri di ricerca
PMI
Interlocutori
Ospedali
Industria
Ricerca clinica
IRCCS
Associazioni di pazienti
[INTERLOCUTORI SALUTE]

16. Joint Research Centre (non-nuclear)
FP7 +
JRC
Joint Research Centre (non-nuclear) +
Euratom
Euratom
© Fit for Health, 2012

17. R&D Chain
© Fit for Health, 2012

18. EUROPEAN COMMISSION - Research DG
7th Framework
Programme
for
Research
Indicative breakdown (€ million)
EUROPEAN COMMISSION - Research DG

19. Collaborative research in the Health theme
Main policy drivers:
Improving health of European citizens
Increasing competitiveness of European health-related industries and businesses
Addressing global health issues, including emerging epidemics
Budget:
€6.1 billion over 7 years ( )

20. Collaborative research
across borders and other barriers
between countries:
at least 3 partners from the 27 EU Member States: Austria, Belgium, Bulgaria, Czech Rep., Cyprus, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Rumania, Slovakia, Slovenia, Spain, Sweden, the United Kingdom.
or the 12 Associated Countries: Albania, Bosnia-Herzegovina, Croatia, FYROM, Iceland, Israel, Liechtenstein, Montenegro, Norway, Serbia, Switzerland, Turkey.
In addition, researchers from anywhere in the world can participate: eg: Australia, Brazil, Canada, China, Egypt, India, Japan, Korea, Russia, South-Africa, USA, … and in many cases, can be funded.

21. Collaborative research
across borders and other barriers
between countries but also:
between different types of organizations Public & private sector: universities, research centres, large companies, small and medium-sized enterprises (SMEs), etc.
between disciplines: multidisciplinary, translational R&D

22. 1. Structure and scope of Health theme

23. The Health Theme Three main activities (“pillars”)
Activity 1:
Biotechnology,
generic tools & technologies
for health
Activity 2:
Translating
research for human health
Activity 3:
Optimising
the delivery
of health care
The Innovative Medicines Initiative
cross-cutting issues: international cooperation, SMEs, child health, ageing populations, gender-related health issues
Activity 4: Support actions & response to policy needs

24. EC Funding Strategy Translational research Clinical capacity Discovery
Research Grants
Product development, PPP
Discovery
Preclinical
Phase I/IIa
Phase II + III
Regulatory
Large Collaborative Projects
EDCTP
Translational
research
Clinical
capacity
Bottlenecks = Innovative Medicine Initiative (IMI)

25. Industry (esp. SME) participation & International Cooperation
Policy aspects
Industry (esp. SME) participation & International Cooperation
Emphasis and special measures for:
Small & Medium-sized Enterprises (SMEs)
Opportunities and support measures
International Cooperation
the possibility to tackle issues on a global scale
an opportunity to extend your networks beyond Europe

26. 2. Basic Principles

27. Submission & evaluation
Basic principles:
Annual calls for proposals (2-stage)
Evaluation by panels of independent experts overseen by Independent Observers
3 criteria:
Science & Technology excellence
Implementation & Management
Potential Impact
Feedback: Evaluation Summary Reports (ESRs)
Experts wanted !
Aim: to fund the best R&D proposals

28. 3. HEALTH 2013 Work Programme

29. Note: there are some exceptions to the ceilings.
Funding schemes for these calls
Note: there are some exceptions to the ceilings.

31. Priorities for Health in 2012-2013
2013 thematic priorities:
Brain research
Anti-microbial resistance
Comparative effectiveness (CER)
Cross-cutting priorities:
Translation of results into applications
Innovation & SMEs
Social innovationSocial innovation refers to new strategies, concepts, ideas and organizations that meet social needs of all kinds - from working conditions and education to community development and health - and that extend and strengthen civil society.
International cooperation

32. HEALTH
FP7-HEALTH-2013-INNOVATION-1 as main call with an indicative budget of EUR 680 million with broader topics of which many are tailored for SME participation (bottom-up with a minimum percentage of EU funding requested going to SMEs)
FP7-HEALTH-2013-INNOVATION-2 as a specific call to boost SME participation for innovative solutions in the health sector with an indicative budget of EUR 140 million. This call has very specific conditions. Maximum project duration is limited to 3 years.
2 STAGE EVALUATION. Max 6 pagine:
1.1 Concept and objectives
1.2 Progress beyond the state-of-the-art
1.3 S/T methodology and associated work plan
2.1 Expected impacts

33. 7th CALL HEALTH Call identifier: FP7-HEALTH-2013-INNOVATION-1
35 topics
Proposal submission and evaluation: two-stage procedure.
Date of publication: 10 July 2012
Deadline for stage 1 proposals: 02 October 2012 at 17:00:00 (Brussels local time)
Indicative budget: EUR 680 million from the 2013 budget
Call identifier: FP7-HEALTH-2013-INNOVATION-2
2 topics
Proposal submission and evaluation: two-stage procedure.
Date of publication: 10 July 2012
Deadline for stage 1 proposals: 25 September 2012 at 17:00:00 (Brussels local time)
Indicative budget: EUR 140 million from the 2013 budget

34. 2013 WP preparation Milestones and meetings
Roadmap discussed at PC meeting: 5 September 2011
Draft WP v1 (“Orientation paper”) => sent to PC by mid-October
Meeting with Advisory Group (9 Nov 2011)
PC meeting (9-10 Nov 2011) to discuss draft WP v1
PC meeting (14 Feb. 2012) to discuss draft WP v2 => final input by 24 February
Internal draft must be ready by 12 March.
Inter-service Consultation (April-May 2012) - draft WP v3
Formal PC consultation (June 2012) - draft WP v4
Work Programme adoption & publication: 10 July 2012

35. Health theme Cross cutting topic relevant to the entire Health theme
0-1 - Boosting the translation of FP projects' results into innovative applications for health. FP7-Health-2013-INNOVATION-2
build on the results of projects funded under Health theme of FP6 & FP7.
focus on specifications, testing and validation of results
applicants must control the IPR to be used in their application
New: SMEs must be from Member States or Associated Countries (conditions specified, further changes to come based on INNOV-2 call)
Funding scheme: CP-FP, max. €6m/project. MS & AC SMEs only. SME-topic: min. 50% EC contribution to SMEs
Indicative budget: €75 million

36. The Health theme
1: Biotechnology, generic tools and medical for technologies for human health
1.1 High-throughput research (closed)
1.2 Detection, diagnosis and monitoring
1.3 Suitability, safety and efficacy of therapies
1.4 Innovative therapeutic approaches and interventions

37. Area 1.2 Detection, Diagnosis and Monitoring37

38. Activity 1 Biotech, tools & technologies
1.2 – Detection, Diagnosis & Monitoring
Development of imaging technologies for therapeutic interventions in rare diseases.
Funding scheme: CP-FP, max. €6m/project. SME-topic: min. 30% EC contribution to SMEs

39. Area 1.3 Suitability, Safety and Efficacy of Medicines39

40. Activity 1 Biotech, tools & technologies
1.3 – Suitability, safety & efficacy of medicines
Modelling toxic responses in case studies for predictive human safety assessment.
Funding scheme: CP-FP, max. €12m/project. Industry topic: min. 15% EC contribution to industry, incl. SMEs
Only one proposal may be selected
Innovative approaches to address adverse immune reactions to biomedical devices, implants & transplant tissues.
Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs

41. Activity 1 Biotech, tools & technologies
1.3 – Suitability, safety & efficacy of medicines
Safety and efficacy of therapeutic vaccines.
Funding scheme: CP-FP, max. €6m/project. Industry topic: min. 30% EC contribution to industry, incl. SMEs
Development of alternative in vitro, analytical, immunochemical, and other test methods for quality control of vaccines.
Funding scheme: CP-FP, max. €6m/project. New: max. 3 years SME topic: min. 30% EC contribution to SMEs

42. Area 1.4 Innovative therapeutic approaches and interventions42

43. Activity 1 Biotech, tools & technologies
Controlling differentiation and proliferation in human stem cells intended for therapeutic use.
Funding scheme: CP-FP, max. €6m/project. SME topic: min. 15% EC contribution to SMEs

44. The Health theme 2: Translating research for human health
2.1 Integrating biological data and processes: large-scale data gathering, systems biology
2.2 Research on the brain and related diseases, human development and ageing
2.3 Translational research in major infectious diseases: to confront major threats to public health
2.4 Translational research in other major diseases

45. Area 2.1.1 Large-scale data gathering45

46. Activity 2 - Translating research for human health
2.1.1 – Large-scale data gathering
Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes.
Funding scheme: CP-IP, max. €12m/project. SME topic: min. 30% EC contribution to SMEs
High impact research initiative on metagenomics for personalised medicine approaches.
Funding scheme: IP, max. €30m/project; max. 1 project Industry topic: min. 30% EC contribution to industry, incl. SMEs
Only one proposal may be selected

47. Research on the brain and brain related diseases
Area 2.2.1
Research on the brain and brain related diseases 47

48. Activity 2 - Translating research for human health
Prospective longitudinal data collection and Comparative Effectiveness Research (CER) for traumatic brain injury (TBI)
Funding scheme: CP-IP, max. €30m/project, one or more projects
Development of effective imaging tools for diagnosis, monitoring and management of mental disorders
Funding scheme: CP-FP, max. €6m/project Industry topic: min. 30% EC contribution to industry, incl. SMEs

49. Activity 2 - Translating research for human health
2.2.1 – The brain and brain disorders
Paediatric conduct disorders characterised by aggressive traits and/or social impairment: from preclinical research to treatment
Funding scheme: CP-FP, max. €6m/project SME topic: min. 15% EC contribution to SMEs
Patho-physiology and therapy of epilepsy and epileptiform disorders
Funding scheme: CP-IP, max. €12m/project SME topic: min. 15% EC contribution to SMEs
– Understanding and combating pain (NEW)
Funding scheme: CP-FP, max. €6m/project

50. 2.3.1 – Antimicrobial drug resistance
Area 2.3
Translational research in major infectious diseases; to confront major threats to public health
2.3.0 – Cross cutting issues
2.3.1 – Antimicrobial drug resistance
2.3.2 – HIV/AIDS, malaria, tuberculosis (closed)
2.3.3 – Potentially new & re-emerging epidemics
2.3.4 – Neglected infectious diseases 50

51. Activity 2 - Translating research for human health
2.3.0 – Cross-cutting priorities
– Innovation in vaccines
Funding scheme: CP-FP, max. €6m/project. SME topic: min. 30% EC contribution to SMEs

52. Activity 2 - Translating research for human health
2.3.1 – Anti-microbial drug resistance
– INNOVATION 2 Drugs and vaccines for infections that have developed or are at risk of developing significant antimicrobial resistance.
New: SMEs must be from Member States or Associated Countries
Funding scheme: CP-FP, max. €6m/project. MS & AC SMEs only. SME topic: min. 50% EC contribution to SMEs
Stratified approaches to antibacterial and/or antifungal treatment
Funding scheme: CP-FP, max. €6m/project.

53. Activity 2 - Translating research for human health
2.3.3 – Potentially new and re-emerging epidemics
– Clinical management of patients in severe epidemics.
Funding scheme: IP, max. €24m/project; max. 1 project

54. Activity 2 - Translating research for human health
2.3.4 – Neglected infectious diseases
– Neglected infectious diseases of Central and Eastern Europe.
Funding scheme: FP, max. €3m/project.
– Drug development for neglected parasitic diseases.
Funding scheme: FP, max. €6m/project.
SME topic: min. 15% EC contribution to SMEs

55. 2.4.1 – Cancer Area 2.4 Translational research in other major diseases
2.4.2 – CVD
2.4.3 – Diabetes/obesity (closed)
2.4.4 – Rare diseases (closed)
2.4.5 – Chronic diseases (closed) 55

56. Activity 2 - Translating research for human health
2.4.1 – Cancer
– Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer.
Funding scheme: CP-FP, max. €6m/project.
– Strengthening the cancer patient's immune system.
Funding scheme: CP-FP, max. €6m/project.
Industry topic: min. 30% EC contribution to industry, incl. SMEs
Investigator-driven supportive and palliative care clinical trials and observational studies.
Funding scheme: CP-FP, max. €6m/project.

57. Activity 2 - Translating research for human health
2.4.2 – Cardiovascular diseases
– Discovery research to reveal novel targets for cardiovascular disease treatment.
Funding scheme: CP-FP, max. €6m/project.
SME topic: min. 30% EC contribution to SMEs
– Comparative effectiveness research of existing technologies for prevention, diagnosis and treatment of cardiovascular diseases.
Funding scheme: CP-FP, max. €6m/project.
: Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan.
Funding scheme: CP-FP, Small €3m/project.

58. The Health Theme
3: Optimising the delivery of healthcare to European citizens
3.1 Translating clinical research into clinical practice
3.2 Quality, efficiency and solidarity of healthcare systems (closed)
3.3 Health promotion and prevention
3.4 International public health & health systems (closed)

59. Activity 3 Optimising the delivery of healthcare
3.1 – Translating clinical research into clinical practice
Comparative Effectiveness Research (CER) in health systems and health services interventions.
Funding scheme: CP-FP, max. €6m/project.
3.3 – Health promotion and prevention
Social innovation for health promotion
Funding scheme: CP-FP, max. €6m/project. SME topic: min. 15% EC contribution to SMEs

60. The Health theme 4: Actions across the Theme
4.1 Coordination & Support Actions across the theme
4.2 Responding to EU policy needs

61. Activity 4 Actions across the theme
4.1 – CSAs across the theme
4.1-1 –Supporting industrial participation in EU-funded research in the Health sector.
Funding scheme: CA, max. €2m/project, up to one project
4.1-2 – Interactions between EU legislation and health research and/or innovation and the effects of its application and implementation on health research and/or innovation.
Funding scheme: SA, max. €0.5m/project, one or more projects

62. Activity 4 Actions across the theme
4.1 – CSAs across the theme
Support for Presidency events. Organisation of supporting actions and events associated to the Presidency of the European Union
"…specifically from mid-2013 to 2015 Presidencies, …"
Funding scheme: SA, max. €0.1m/project, one or more projects
Preparing the future for health research and innovation.
Funding scheme: SA, max. €0.5m/project, one or more projects
   4.1-5: Global initiative on gene-environment interactions in diabetes/obesity in specific populations.
Funding scheme: CA, max. €2m/project, up to one project
   4.1-6: Mapping chronic non-communicable diseases research activities
Funding scheme: CA, max. €1m/project, up to one project

63. Activity 4 Actions across the theme
4.2 – Responding to EU policy needs
Investigator-driven clinical trials for off-patent medicines using innovative, age-appropriate formulations and/or delivery systems.
Funding scheme: CP-FP, max. €6m/project.
Industry topic: min. 30% EC contribution to industry, incl. SMEs.
Adverse drug reaction research.
Funding scheme: CP-FP, max. €3m/project.
SME topic: min. 15 % EC contribution to SMEs.
New methodologies for clinical trials for small population groups.
Funding scheme: CP-FP, max. €3m/project.

64. All proposals must address these questions.
Ethics: overview (1)
Two main questions asked on ethics:
 The necessity to use i.e. personal data, animals, human tissue in order to achieve the scientific objectives set forth in the proposal. Is there an alternative ?
 Benefit/burden balance of the research project. What will be the impact of this research, not only regarding scientific advance, but also in terms of human dignity as well as social and cultural impact ?
All proposals must address these questions.

65. Ethics: overview (2)
Applicants must first identify key ethical issues raised by their proposals and explain how they will address them.
The main issues are:
Informed Consent
Research on Human embryos/foetuses
Data Protection and Privacy
Research on Animals (the ‘3Rs’: Reduce, Replace, Refine)
Research involving Developing Countries
Dual use (research that could have military applications)
3 areas are excluded from funding:
- Human reproductive cloning
- Intentional germ line modification (except research relating to cancer of the gonads which can be funded)
- Creation of human embryos for research or stem cell procurement (including by means of somatic cell nuclear transfer)

66. 5. Identification of opportunities for health researchers under other FP7 themes: KBBE, ICT, NMP, SSH…

68. Other funding opportunities for health research within the Cooperation Specific Programme

69. Other funding opportunities for health research within the
KBBE theme
Call identifier: FP7-KBBE
Proposal submission and evaluation: one-stage procedure.
Date of publication: 10 July 2012
Deadline for stage 1 proposals: 5 February 2013 at 17:00 (Brussels local time)
Indicative budget: EUR 680 million from the 2013 budget –
Call 7(WP2013)
• Research and Innovation for the benefit of society, with a challenges driven approach to maximize the impact of research funded by the EU
• 4 main challenges: the main pillars of bio-economySustainable
1) Agriculture and Forestry
2) Safe and Sustainable Food and Health Diets
3) Unlocking the potential of Aquatic Living Resources
4) Sustainable and Competitive Bio-based Industries
• Broader topics in terms of budget and research developed, leaving greater freedom to the research community

70. Area – Consumers
Impact of food and nutritional behaviour, lifestyle and the socio-economic environment on depression and proposed remedial actions (LCP, Up to one project )
Area Nutrition
New technologies to study brain function in relation to eating behaviours and mental well-being (LCP, Up to one project )
Factors influencing the human gut microbiome and its effect on the development of diet related diseases and brain development (LCP, Up to one project )

71. KBBE topics
KBBE : Impact of food and nutritional behaviour, lifestyle and the socioeconomic environment on depression and proposed remedial actions (Max 1 CP-IP. Max EC contribution: 6 M€)
KBBE : New technologies to study brain function in relation to eating Behaviour (Max 1 CP-IP. Max EC contribution: 9 M€)
KBBE : Factors influencing the human gut microbiome and its effect on the development of diet-related diseases and brain development (Max 1 CP-IP. Max EC contribution: 9 M€)
KBBE : Food-based solutions for eradication of vitamin D deficiency and health promotion throughout the life cycle (Max 1 CP-IP. Max EC contribution: 6 M€)

72. Other funding opportunities for health research within the
ICT theme
BUDGET € Million
APERTURA DEADLINE
FP7-ICT
10 Luglio 2012
15 Gennaio 2013 (734M€ from budget 2013)
FP7-ICT
18 Settembre 2012
16 Aprile 2013 (242M€ from budget 2013)
FP NMP-ICT-FoF
4 Dicembre 2012 (70M€ from budget 2013)
FP NMP-ENV-ENERGY-ICT-EeB
4 December 2012 (40M€ from budget 2013)
FP ICT-GC
FP7-ICT-2013-SME-DCA
15 Gennaio 2013 (20M€ from budget 2013)
FP7-ICT-2013-FET-F
23 Ottobre 2012 (100M€ from budget 2013)
FP7-ICT-2013-C
12 Marzo 2013 (50M€ from budget 2013)
FP7-ICT-2013-X
12 Settembre 2012
29 Gennaio 2013 (15M€ from budget 2013)
FP7-ICT2013-EU-Japan
2 Ottobre 2012
29 Novembre 2012 (9M€ from budget 2013)
FP7-ICT2013-EU-Brasil
24 Ottobre 2012 (4M€ from budget 2013)
WP2013 will support the European Innovation Partnerships on Active and Healthy Ageing (EIP AHA) on Personalized health, active ageing, and independent living
ICTs have a catalytic impact in three key areas:
Productivity and innovation, by facilitating creativity and management
Modernisation of public services, such as health, education and transport.
Advances in science and technology, by supporting cooperation and access to information.

73. Challenge 5: ICT for Health, Ageing Well, Inclusion and Governance:
Personalized health, active ageing, and independent living
Personalized Guidance Services for lifestyle management and disease prevention.
Personalized Guidance Services for management of co-morbidities and integrated care.
Personalized Services for Independent Living and Active Ageing.
Coordination and Support Actions.
Virtual Physiological Human Clinical proof of concept of patient specific computer based models
Personal Health Forecasting.
Coordination and Support Action to develop an RTD roadmap preparing the ground for in-silico clinical trials
ICT for smart and personalised inclusion
Accessible and intuitive solutions for personalised interfaces to smart environments and innovative services.

74. Other funding opportunities for health research within the
NMP theme
Work Programme 2013 Priorities
PPPs (Green Cars, Factories of the Future Energy Efficient Buildings): ~ 36%
Cross cutting innovation : ~12%
Application-specific innovation : ~26%
Raw Materials: ~3%
Energy : ~5%
Environment/Sustainability: ~9%
Health and safety: ~9%
NMP Nanotherapeutics to treat bacterial infectious diseases
NMP Biomaterials for Advanced Therapies and Medical Devices in the neurological/neuromuscular or cardiovascular fields
NMP Biomaterials: Imaging and rapid precise prototyping technology for custom made scaffolds – coordinated call with China

75. Other funding opportunities for health research within the
ENV theme
Call identifier: FP7-ENV-2013-two stage
Proposal submission and evaluation: two-stage procedure.
Date of publication: 10 July 2012
Deadline for stage 1 proposals: 16 October 2012 at 17:00:00 (Brussels local time)
Indicative budget: EUR million from the 2013 budget
CHALLENGE 6.4 PROTECTING CITIZENS FROM ENVIRONMENTAL HAZARDS
ENV Assessing individual exposure to environmental stressors and predicting health outcomes: paving the way for an EU-wide assessment (CP, Up to one project )
ENV Closing gaps of knowledge and reducing exposure to electromagnetic fields (EMF) (CP, Up to one project )

76. Other funding opportunities for health research within the
SSH theme
Call identifier: FP7-SSH
Proposal submission and evaluation: one-stage procedure.
Date of publication: 12 July 2012
Deadline for stage 1 proposals: 31 January 2013 at Brussels local time
Indicative budget: EUR
Draft Work Programme 2013:
SSH The impact of ageing societies on public finances in Europe Health care,
SSH Early childhood education and care and the cost of inequities
SSH The impact of the third sector on socio-economic development in Europe

77. Other funding opportunities for health research within the
SPACE theme
Call identifier: FP7-SPACE
Proposal submission and evaluation: one-stage procedure.
Date of publication: 12 July 2012
Deadline: 21 November 2012, at , Brussels local time
Indicative budget: EUR 126 million
Research and development on next generation products and service lines derived from space-borne data in conjunction with in-situ data is to be targeted
Activities could target applications on areas like:
Health services, or monitoring conditions for vector borne diseases
(…)
Earth-analogue research preparing for space exploration

78. 6. Other EU funding opportunities for Health researchers

80. 7. Sources of information and partners

82. An open, pan-European infrastructure for information on research projects & results within Health Science

86. HEALTH-NCP-NET
Your Support Network

87. [FIND A PARTNER]

88. Pagina Salute, Sito APRE
CORDIS:
CORDIS:
Fitforhealth:
Healthncpnet:
Healthcompentence:

89. PRESENTAZIONE IN 2 STAGE

90. 4. Key issues for success

91. Advice for submission & evaluation (1)
Basics
Eligibility issues - funding scheme, number of partners (esp. for SICA), funding limits, deadlines
Scope of proposal with respects to topic (Relevance) “The topic, the whole topic and nothing but the topic ” also pay attention to introduction in work programme and any specific requirements for industry or international participation
Size and composition of the consortium - beyond the minimum rules, there are no constraints: bring together the competences needed to do the job.
No bonus points for “political correctness” or large consortia

92. Advice for submission & evaluation (2)
Basics
Address all 3 criteria – be explicit to evaluators
Address the Ethics issues Clear requirements for information on ethics issues* - you must explain what the issues are in the proposal - and how will you manage them
Failing to do so can delay negotiation or even exclude a proposal.
Respect basic rules and guidelines - font size (legibility) and page number limitations (excess pages will not be considered in the evaluation)
*Guide for Applicants, Annex 4, section 4.

93. Key factors for success in applying for FP7 funding
Competition is tough : only the best projects get funded
the proposal must address the topic and the work programme (not wishful thinking)
the consortium of partners must be excellent and competent for the tasks (select the right partners)
the proposal must address all 3 criteria,
convince the evaluators (don’t rely on reputation)
and, of course, respect the basic rules. (deadlines, n° of participants, ceilings, length, ethics…)

94. Thanks for your attention !
Health NCP for ITALY
APRE,
Agenzia per la promozione della Ricerca Europea
Via Cavour 71, Roma